Immunogenetics

, Volume 61, Issue 5, pp 327–339 | Cite as

Mhc haplotype H6 is associated with sustained control of SIVmac251 infection in Mauritian cynomolgus macaques

  • Edward T. Mee
  • Neil Berry
  • Claire Ham
  • Ulrike Sauermann
  • Maria T. Maggiorella
  • Frédéric Martinon
  • Ernst J. Verschoor
  • Jonathan L. Heeney
  • Roger Le Grand
  • Fausto Titti
  • Neil Almond
  • Nicola J. Rose
Original Paper

Abstract

The restricted diversity of the major histocompatibility complex (MHC) of Mauritian cynomolgus macaques provides powerful opportunities for insight into host-viral interactions and cellular immune responses that restrict lentiviral infections. However, little is known about the effects of Mhc haplotypes on control of SIV in this species. Using microsatellite-based genotyping and allele-specific PCR, Mhc haplotypes were deduced for 35 macaques infected with the same stock of SIVmac251. Class I haplotype H6 was associated with a reduction in chronic phase viraemia (p = 0.0145) while a similar association was observed for H6 class II (p = 0.0063). An increase in chronic phase viraemia, albeit an insignificant trend, was observed in haplotype H5-positive animals. These results further emphasise the value of genetically defined populations of non-human primates in AIDS research and provide a foundation for detailed characterisation of MHC restricted cellular immune responses and the effects of host genetics on SIV replication in cynomolgus macaques.

Keywords

Non-human primate Macaca fascicularis Genotype AIDS SIV 

Supplementary material

251_2009_369_MOESM1_ESM.doc (40 kb)
Supplemental Table 1Treatment regimens and infection outcome of animals included in study (DOC 39 kb)

References

  1. Almond N, Stott J (1999) Live attenuated SIV—a model of a vaccine for AIDS. Immunol Lett 66:167–170. doi:10.1016/S0165-2478(98) 00153-9 PubMedCrossRefGoogle Scholar
  2. Berry N, Stebbings R, Brown S, Christian P, Thorstensson R, Ahmed RK, Davis L, Ferguson D, D'Arcy N, Elsley W, Hull R, Lines J, Wade-Evans A, Stott J, Almond N (2007) Immunological responses and viral modulatory effects of vaccination with recombinant modified vaccinia virus Ankara (rMVA) expressing structural and regulatory transgenes of simian immunodeficiency virus (SIVmac32H/J5M). J Med Primatol 36:80–94. doi:10.1111/j.1600-0684.2007.00216.x PubMedCrossRefGoogle Scholar
  3. Berry N, Stebbings R, Ferguson D, Ham C, Alden J, Brown S, Jenkins A, Lines J, Duffy L, Davis L, Elsley W, Page M, Hull R, Stott J, Almond N (2008) Resistance to superinfection by a vigorously replicating, uncloned stock of simian immunodeficiency virus (SIVmac251) stimulates replication of a live attenuated virus vaccine (SIVmacC8). J Gen Virol 89:2240–2251. doi:10.1099/vir.0.2008/001693-0 PubMedCrossRefGoogle Scholar
  4. Bihl F, Frahm N, Di Giammarino L, Sidney J, John M, Yusim K, Woodberry T, Sango K, Hewitt HS, Henry L, Linde CH, Chisholm JV 3rd, Zaman TM, Pae E, Mallal S, Walker BD, Sette A, Korber BT, Heckerman D, Brander C (2006) Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses. J Immunol 176:4094–4101PubMedGoogle Scholar
  5. Bimber BN, Moreland AJ, Wiseman RW, Hughes AL, O'Connor DH (2008) Complete characterization of killer Ig-like receptor (KIR) haplotypes in Mauritian cynomolgus macaques: novel insights into nonhuman primate KIR gene content and organization. J Immunol 181:6301–6308PubMedGoogle Scholar
  6. Borsetti A, Baroncelli S, Maggiorella MT, Bellino S, Moretti S, Sernicola L, Belli R, Ridolfi B, Farcomeni S, Negri DR, Cafaro A, Ensoli B, Titti F (2008) Viral outcome of simian-human immunodeficiency virus SHIV-89.6P adapted to cynomolgus monkeys. Arch Virol 153:463–472. doi:10.1007/s00705-007-0009-2 PubMedCrossRefGoogle Scholar
  7. Brandin E, Thorstensson R, Bonhoeffer S, Albert J (2006) Rapid viral decay in simian immunodeficiency virus-infected macaques receiving quadruple antiretroviral therapy. J Virol 80:9861–9864. doi:10.1128/JVI.00394-06 PubMedCrossRefGoogle Scholar
  8. Dittmer U, Petry H, Stahl-Hennig C, Nisslein T, Spring M, Luke W, Bodemer W, Kaup FJ, Hunsmann G (1996) T cell apoptosis in human immunodeficiency virus type 2- and simian immunodeficiency virus-infected macaques. J Gen Virol 77:2433–2436. doi:10.1099/0022-1317-77-10-2433 PubMedCrossRefGoogle Scholar
  9. Feichtinger H, Putkonen P, Parravicini C, Li SL, Kaaya EE, Bottiger D, Biberfeld G, Biberfeld P (1990) Malignant lymphomas in cynomolgus monkeys infected with simian immunodeficiency virus. Am J Pathol 137:1311–1315PubMedGoogle Scholar
  10. Florese RH, Wiseman RW, Venzon D, Karl JA, Demberg T, Larsen K, Flanary L, Kalyanaraman VS, Pal R, Titti F, Patterson LJ, Heath MJ, O'Connor DH, Cafaro A, Ensoli B, Robert-Guroff M (2008) Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV(89.6P) infection. Vaccine 26:3312–3321. doi:10.1016/j.vaccine.2008.03.100 PubMedCrossRefGoogle Scholar
  11. Gaudieri S, DeSantis D, McKinnon E, Moore C, Nolan D, Witt CS, Mallal SA, Christiansen FT (2005) Killer immunoglobulin-like receptors and HLA act both independently and synergistically to modify HIV disease progression. Genes Immun 6:683–690PubMedGoogle Scholar
  12. Gillespie GM, Kaul R, Dong T, Yang HB, Rostron T, Bwayo JJ, Kiama P, Peto T, Plummer FA, McMichael AJ, Rowland-Jones SL (2002) Cross-reactive cytotoxic T lymphocytes against a HIV-1 p24 epitope in slow progressors with B*57. AIDS 16:961–972. doi:10.1097/00002030-200205030-00002 PubMedCrossRefGoogle Scholar
  13. Giraldo-Vela JP, Rudersdorf R, Chung C, Qi Y, Wallace LT, Bimber B, Borchardt GJ, Fisk DL, Glidden CE, Loffredo JT, Piaskowski SM, Furlott JR, Morales-Martinez JP, Wilson NA, Rehrauer WM, Lifson JD, Carrington M, Watkins DI (2008) The major histocompatibility complex class II alleles Mamu-DRB1*1003 and -DRB1*0306 are enriched in a cohort of simian immunodeficiency virus-infected rhesus macaque elite controllers. J Virol 82:859–870. doi:10.1128/JVI.01816-07 PubMedCrossRefGoogle Scholar
  14. Gotch FM, Hovell R, Delchambre M, Silvera P, McMichael AJ (1991) Cytotoxic T-cell response to simian immunodeficiency virus by cynomolgus macaque monkeys immunized with recombinant vaccinia virus. AIDS 5:317–320. doi:10.1097/00002030-199103000-00012 PubMedCrossRefGoogle Scholar
  15. Habis A, Baskin GB, Murphey-Corb M, Levy LS (1999) Simian AIDS-associated lymphoma in rhesus and cynomolgus monkeys recapitulates the primary pathobiological features of AIDS-associated non-Hodgkin's lymphoma. AIDS Res Hum Retroviruses 15:1389–1398. doi:10.1089/088922299310098 PubMedCrossRefGoogle Scholar
  16. Hardie RA, Knight E, Bruneau B, Semeniuk C, Gill K, Nagelkerke N, Kimani J, Wachihi C, Ngugi E, Luo M, Plummer FA (2008a) A common human leucocyte antigen-DP genotype is associated with resistance to HIV-1 infection in Kenyan sex workers. AIDS 22:2038–2042. doi:10.1097/QAD.0b013e328311d1a0 PubMedCrossRefGoogle Scholar
  17. Hardie RA, Luo M, Bruneau B, Knight E, Nagelkerke NJ, Kimani J, Wachihi C, Ngugi EN, Plummer FA (2008b) Human leukocyte antigen-DQ alleles and haplotypes and their associations with resistance and susceptibility to HIV-1 infection. AIDS 22:807–816. doi:10.1097/QAD.0b013e3282f51b71 PubMedCrossRefGoogle Scholar
  18. Jorajuria S, Clayette P, Dereuddre-Bosquet N, Larghero J, Thiebot H, Neildez O, Vaslin B, Le Grand R, Dormont D (2000) Evaluation of the effect of early and massive tritherapy on the expression of cellular factors potentially implicated in antiretroviral therapy resistance. Pathol Biol (Paris) 48:490–494Google Scholar
  19. Kaslow RA, Carrington M, Apple R, Park L, Munoz A, Saah AJ, Goedert JJ, Winkler C, O'Brien SJ, Rinaldo C, Detels R, Blattner W, Phair J, Erlich H, Mann DL (1996) Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 2:405–411. doi:10.1038/nm0496-405 PubMedCrossRefGoogle Scholar
  20. Kiepiela P, Leslie AJ, Honeyborne I, Ramduth D, Thobakgale C, Chetty S, Rathnavalu P, Moore C, Pfafferott KJ, Hilton L, Zimbwa P, Moore S, Allen T, Brander C, Addo MM, Altfeld M, James I, Mallal S, Bunce M, Barber LD, Szinger J, Day C, Klenerman P, Mullins J, Korber B, Coovadia HM, Walker BD, Goulder PJ (2004) Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 432:769–775. doi:10.1038/nature03113 PubMedCrossRefGoogle Scholar
  21. Lacap PA, Huntington JD, Luo M, Nagelkerke NJ, Bielawny T, Kimani J, Wachihi C, Ngugi EN, Plummer FA (2008) Associations of human leukocyte antigen DRB with resistance or susceptibility to HIV-1 infection in the Pumwani Sex Worker Cohort. AIDS 22:1029–1038. doi:10.1097/QAD.0b013e3282ffb3db PubMedCrossRefGoogle Scholar
  22. Le Grand R, Clayette P, Noack O, Vaslin B, Theodoro F, Michel G, Roques P, Dormont D (1994) An animal model for antilentiviral therapy: effect of zidovudine on viral load during acute infection after exposure of macaques to simian immunodeficiency virus. AIDS Res Hum Retroviruses 10:1279–1287PubMedCrossRefGoogle Scholar
  23. Loffredo JT, Friedrich TC, Leon EJ, Stephany JJ, Rodrigues DS, Spencer SP, Bean AT, Beal DR, Burwitz BJ, Rudersdorf RA, Wallace LT, Piaskowski SM, May GE, Sidney J, Gostick E, Wilson NA, Price DA, Kallas EG, Piontkivska H, Hughes AL, Sette A, Watkins DI (2007a) CD8 T cells from SIV elite controller macaques recognize Mamu-B*08-bound epitopes and select for widespread viral variation. PLoS One 2:e1152. doi:10.1371/journal.pone.0001152 PubMedCrossRefGoogle Scholar
  24. Loffredo JT, Maxwell J, Qi Y, Glidden CE, Borchardt GJ, Soma T, Bean AT, Beal DR, Wilson NA, Rehrauer WM, Lifson JD, Carrington M, Watkins DI (2007b) Mamu-B*08-positive macaques control simian immunodeficiency virus replication. J Virol 81:8827–8832. doi:10.1128/JVI.00895-07 PubMedCrossRefGoogle Scholar
  25. Maggiorella MT, Monardo F, Koanga-Mogtomo ML, Cioe L, Sernicola L, Corrias F, Baroni CD, Verani P, Titti F (1998) Detection of infectious simian immunodeficiency virus in B- and T-cell lymphomas of experimentally infected macaques. Blood 91:3103–3111PubMedGoogle Scholar
  26. Maggiorella MT, Sernicola L, Crostarosa F, Belli R, Pavone-Cossut MR, Macchia I, Farcomeni S, Tenner-Racz K, Racz P, Ensoli B, Titti F (2007) Multiprotein genetic vaccine in the SIV-Macaca animal model: a promising approach to generate sterilizing immunity to HIV infection. J Med Primatol 36:180–194. doi:10.1111/j.1600-0684.2007.00236.x PubMedCrossRefGoogle Scholar
  27. Martin MP, Gao X, Lee JH, Nelson GW, Detels R, Goedert JJ, Buchbinder S, Hoots K, Vlahov D, Trowsdale J, Wilson M, O'Brien SJ, Carrington M (2002) Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 31:429–434PubMedGoogle Scholar
  28. Martin MP, Qi Y, Gao X, Yamada E, Martin JN, Pereyra F, Colombo S, Brown EE, Shupert WL, Phair J, Goedert JJ, Buchbinder S, Kirk GD, Telenti A, Connors M, O'Brien S, Walker J, Parham BD, Deeks P, Mc SG, Vicar DW, Carrington M (2007) Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet 39:733–740. doi:10.1038/ng2035 PubMedCrossRefGoogle Scholar
  29. McNeil AJ, Yap PL, Gore SM, Brettle RP, McColl M, Wyld R, Davidson S, Weightman R, Richardson AM, Robertson JR (1996) Association of HLA types A1-B8-DR3 and B27 with rapid and slow progression of HIV disease. QJM 89:177–185PubMedGoogle Scholar
  30. Mee ET, Murrell CK, Sauermann U, Wilkinson RC, Cutler K, North D, Heath A, Ladhani K, Almond N, Rose NJ (2008) The Mhc class II DRB genotype of Macaca fascicularis does not influence infection by simian retrovirus type 2. Tissue Antigens 72:369–378. doi:10.1111/j.1399-0039.2008.01114.x PubMedCrossRefGoogle Scholar
  31. Mee ET, Badhan A, Karl JA, Wiseman RW, Cutler K, Knapp LA, Almond N, O'Connor DH, Rose NJ (2009) MHC haplotype frequencies in a UK breeding colony of Mauritian cynomolgus macaques mirror those found in a distinct population from the same geographic origin. J Med Primatol 38:1–14. doi:10.1111/j.1600-0684.2008.00299.x PubMedCrossRefGoogle Scholar
  32. Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, Martino L, Hallahan CW, Selig SM, Schwartz D, Sullivan J, Connors M (2000) HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci U S A 97:2709–2714. doi:10.1073/pnas.050567397 PubMedCrossRefGoogle Scholar
  33. Montgomery MM, Dean AF, Taffs F, Stott EJ, Lantos PL, Luthert PJ (1999) Progressive dendritic pathology in cynomolgus macaques infected with simian immunodeficiency virus. Neuropathol Appl Neurobiol 25:11–19. doi:10.1046/j.1365-2990.1999.00163.x PubMedCrossRefGoogle Scholar
  34. Mothe BR, Weinfurter J, Wang C, Rehrauer W, Wilson N, Allen TM, Allison DB, Watkins DI (2003) Expression of the major histocompatibility complex class I molecule Mamu-A*01 is associated with control of simian immunodeficiency virus SIVmac239 replication. J Virol 77:2736–2740. doi:10.1128/JVI.77.4.2736-2740.2003 PubMedCrossRefGoogle Scholar
  35. Muhl T, Krawczak M, Ten Haaft P, Hunsmann G, Sauermann U (2002) MHC class I alleles influence set-point viral load and survival time in simian immunodeficiency virus-infected rhesus monkeys. J Immunol 169:3438–3446PubMedGoogle Scholar
  36. Ndung'u T, Gaseitsiwe S, Sepako E, Doualla-Bell F, Peter T, Kim S, Thior I, Novitsky VA, Essex M (2005) Major histocompatibility complex class II (HLA-DRB and -DQB) allele frequencies in Botswana: association with human immunodeficiency virus type 1 infection. Clin Diagn Lab Immunol 12:1020–1028. doi:10.1128/CDLI.12.9.1020-1028.2005 PubMedGoogle Scholar
  37. Negri DR, Baroncelli S, Catone S, Comini A, Michelini Z, Maggiorella MT, Sernicola L, Crostarosa F, Belli R, Mancini MG, Farcomeni S, Fagrouch Z, Ciccozzi M, Boros S, Liljestrom P, Norley S, Heeney J, Titti F (2004) Protective efficacy of a multicomponent vector vaccine in cynomolgus monkeys after intrarectal simian immunodeficiency virus challenge. J Gen Virol 85:1191–1201. doi:10.1099/vir.0.79794-0 PubMedCrossRefGoogle Scholar
  38. Neildez O, Le Grand R, Caufour P, Vaslin B, Cheret A, Matheux F, Theodoro F, Roques P, Dormont D (1998) Selective quasispecies transmission after systemic or mucosal exposure of macaques to simian immunodeficiency virus. Virology 243:12–20. doi:10.1006/viro.1997.9026 PubMedCrossRefGoogle Scholar
  39. Nelson GW, Kaslow R, Mann DL (1997) Frequency of HLA allele-specific peptide motifs in HIV-1 proteins correlates with the allele's association with relative rates of disease progression after HIV-1 infection. Proc Natl Acad Sci U S A 94:9802–9807. doi:10.1073/pnas.94.18.9802 PubMedCrossRefGoogle Scholar
  40. Nilsson C, Makitalo B, Berglund P, Bex F, Liljestrom P, Sutter G, Erfle V, ten Haaft P, Heeney J, Biberfeld G, Thorstensson R (2001) Enhanced simian immunodeficiency virus-specific immune responses in macaques induced by priming with recombinant Semliki Forest virus and boosting with modified vaccinia virus Ankara. Vaccine 19:3526–3536. doi:10.1016/S0264-410X(01) 00034-2 PubMedCrossRefGoogle Scholar
  41. O'Connor DH, Mothe BR, Weinfurter JT, Fuenger S, Rehrauer WM, Jing P, Rudersdorf RR, Liebl ME, Krebs K, Vasquez J, Dodds E, Loffredo J, Martin S, McDermott AB, Allen TM, Wang C, Doxiadis GG, Montefiori DC, Hughes A, Burton DR, Allison DB, Wolinsky SM, Bontrop R, Picker LJ, Watkins DI (2003) Major histocompatibility complex class I alleles associated with slow simian immunodeficiency virus disease progression bind epitopes recognized by dominant acute-phase cytotoxic-T-lymphocyte responses. J Virol 77:9029–9040. doi:10.1128/JVI.77.16.9029-9040.2003 PubMedCrossRefGoogle Scholar
  42. Putkonen P, Warstedt K, Thorstensson R, Benthin R, Albert J, Lundgren B, Oberg B, Norrby E, Biberfeld G (1989) Experimental infection of cynomolgus monkeys (Macaca fascicularis) with simian immunodeficiency virus (SIVsm). J Acquir Immune Defic Syndr 2:359–365PubMedGoogle Scholar
  43. Putkonen P, Quesada-Rolander M, Leandersson AC, Schwartz S, Thorstensson R, Okuda K, Wahren B, Hinkula J (1998) Immune responses but no protection against SHIV by gene-gun delivery of HIV-1 DNA followed by recombinant subunit protein boosts. Virology 250:293–301. doi:10.1006/viro.1998.9379 PubMedCrossRefGoogle Scholar
  44. Stebbings RJ, Almond NM, Stott EJ, Berry N, Wade-Evans AM, Hull R, Lines J, Silvera P, Sangster R, Corcoran T, Rose J, Walker KB (2002) Mechanisms of protection induced by attenuated simian immunodeficiency virus. Virology 296:338–353. doi:10.1006/viro.2002.1379 PubMedCrossRefGoogle Scholar
  45. Stebbings R, Berry N, Stott J, Hull R, Walker B, Lines J, Elsley W, Brown S, Wade-Evans A, Davis G, Cowie J, Sethi M, Almond N (2004) Vaccination with live attenuated simian immunodeficiency virus for 21 days protects against superinfection. Virology 330:249–260. doi:10.1016/j.virol.2004.09.026 PubMedCrossRefGoogle Scholar
  46. ten Haaft P, Verstrepen B, Uberla K, Rosenwirth B, Heeney J (1998) A pathogenic threshold of virus load defined in simian immunodeficiency virus- or simian-human immunodeficiency virus-infected macaques. J Virol 72:10281–10285PubMedGoogle Scholar
  47. ten Haaft P, Almond N, Biberfeld G, Cafaro A, Cranage M, Ensoli B, Hunsmann G, Polyanskaya N, Stahl-Hennig C, Thortensson R, Titti F, Heeney J (2001) Comparison of early plasma RNA loads in different macaque species and the impact of different routes of exposure on SIV/SHIV infection. J Med Primatol 30:207–214. doi:10.1034/j.1600-0684.2001.d01-54.x PubMedCrossRefGoogle Scholar
  48. Titti F, Sernicola L, Geraci A, Panzini G, Di Fabio S, Belli R, Monardo F, Borsetti A, Maggiorella MT, Koanga-Mogtomo M, Corrias F, Zamarchi R, Amadori A, Chieco-Bianchi L, Verani P (1997) Live attenuated simian immunodeficiency virus prevents super-infection by cloned SIVmac251 in cynomolgus monkeys. J Gen Virol 78(Pt 10):2529–2539PubMedGoogle Scholar
  49. Tsai CC, Emau P, Follis KE, Beck TW, Benveniste RE, Bischofberger N, Lifson JD, Morton WR (1998) Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol 72:4265–4273PubMedGoogle Scholar
  50. Wade-Evans AM, Stott J, Hanke T, Stebbings R, Berry N, Lines J, Sangster R, Silvera P, Walker B, MacManus S, Davis G, Cowie J, Arnold C, Hull R, Almond N (2001) Specific proliferative T cell responses and antibodies elicited by vaccination with simian immunodeficiency virus Nef do not confer protection against virus challenge. AIDS Res Hum Retroviruses 17:1517–1526. doi:10.1089/08892220152644223 PubMedCrossRefGoogle Scholar
  51. Wiseman RW, Wojcechowskyj JA, Greene JM, Blasky AJ, Gopon T, Soma T, Friedrich TC, O'Connor SL, O'Connor DH (2007) Simian immunodeficiency virus SIVmac239 infection of major histocompatibility complex-identical cynomolgus macaques from Mauritius. J Virol 81:349–361. doi:10.1128/JVI.01841-06 PubMedCrossRefGoogle Scholar
  52. Yant LJ, Friedrich TC, Johnson RC, May GE, Maness NJ, Enz AM, Lifson JD, O'Connor DH, Carrington M, Watkins DI (2006) The high-frequency major histocompatibility complex class I allele Mamu-B*17 is associated with control of simian immunodeficiency virus SIVmac239 replication. J Virol 80:5074–5077. doi:10.1128/JVI.80.10.5074-5077.2006 PubMedCrossRefGoogle Scholar
  53. Zhang ZQ, Fu TM, Casimiro DR, Davies ME, Liang X, Schleif WA, Handt L, Tussey L, Chen M, Tang A, Wilson KA, Trigona WL, Freed DC, Tan CY, Horton M, Emini EA, Shiver JW (2002) Mamu-A*01 allele-mediated attenuation of disease progression in simian-human immunodeficiency virus infection. J Virol 76:12845–12854. doi:10.1128/JVI.76.24.12845-12854.2002 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Edward T. Mee
    • 1
  • Neil Berry
    • 1
  • Claire Ham
    • 1
  • Ulrike Sauermann
    • 2
  • Maria T. Maggiorella
    • 3
  • Frédéric Martinon
    • 4
    • 5
  • Ernst J. Verschoor
    • 6
  • Jonathan L. Heeney
    • 6
    • 7
  • Roger Le Grand
    • 4
    • 5
  • Fausto Titti
    • 3
  • Neil Almond
    • 1
  • Nicola J. Rose
    • 1
  1. 1.Division of RetrovirologyNational Institute for Biological Standards and ControlHertfordshireUK
  2. 2.German Primate Centre, Working Group Infection ModelsGöttingenGermany
  3. 3.Division of Experimental Retrovirology and Non-Human Primate Models, National AIDS CenterIstituto Superiore di SanitàRomeItaly
  4. 4.CEA, Division of Immuno-VirologyInstitute of Emerging Diseases and Innovative Therapies, DSVFontenay aux RosesFrance
  5. 5.Université Paris-SudOrsayFrance
  6. 6.Department of VirologyBiomedical Primate Research CentreRijswijkThe Netherlands
  7. 7.Department of Veterinary MedicineUniversity of CambridgeCambridgeUK

Personalised recommendations